Metabolism and ExcretionPhase 1NCT02046213
An Open-label, Single-dose Study to Determine the Metabolism and Excretion of [14C]E2006 in Healthy Male Subjects
A Phase 1 study testing E2006 in people with Metabolism and Excretion, run by Eisai Inc. at 1 site in United States.
Trial summary
The purpose of this study is to determine the metabolism and excretion of [14C]E2006 in healthy male subjects. Read more about this study
- Who is it for?
- Ages 18 to 55 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Metabolism and Excretion
- What is being tested?
- E2006
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 16 participants
- Where
- 1 siteUnited States
- Study dates
- Feb 2014to May 2014
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy male 18 to 55 years, inclusive, at the time of informed consent
- Body mass index (BMI) of 18 to 32 kg/m2 at Screening
- Must have had a successful vasectomy (confirmed azoospermia) or they and their female partners must not be of childbearing potential or must be practicing highly effective contraception throughout the study period and for 90 days after study drug discontinuation. No sperm donation is allowed during the study period and for 90 days after study drug discontinuation.
- Provide written informed consent
- Willing and able to comply with all aspects of the protocol
Who cannot join
- Participated in a 14C research study within the 6 months prior to Day -2. The total radiation exposure to radiolabelled compounds from this study and any previous studies must be within the recommended levels considered safe (per US 21 CFR 361.1)
- Exposure to clinically significant radiation (greater than 100 milliseiverts) within 12 months prior to Day -2
- Any history of cerebrovascular disease (stroke or transient ischemic attack)
- A prolonged QT/QTc interval (QTc greater than 450 msec) as demonstrated upon confirmatory ECG if first ECG indicates prolonged QT/QTc interval
- History of prolonged QT/QTc interval
- History of risk factors for torsade de pointes (e.g., heart failure, hypokalemia, family history of long QT syndrome) or the use of concomitant medications that prolonged the QT/QTc interval
Show all 28Show fewer
- Heart rate less than 40 or greater than 100 beats/min at Screening or Baseline
- History of ischemic heart disease (e.g., acute coronary syndromes, stable angina), syncope or cardiac arrhythmias
- Systolic blood pressure greater than 140 mmHg or less than 90 mmHg or diastolic blood pressure greater than 90 mmHg or less than 60 mmHg at Screening or Baseline
- Hemoglobin less than 12.5 g/dL or hemotocrit less than or equal to 38% at Baseline check-in
- Evidence of clinically significant disease (e.g., psychiatric disorders, disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system) that in the opinion of the investigator(s) could affect the subject's safety or interfere with the study assessments
- Any laboratory abnormalities considered clinically significant by the investigator
- Clinically significant illness which required medical treatment within 8 weeks of dosing or a clinically significant infection within 4 weeks of dosing
- Any history of gastrointestinal surgery (e.g., hepatectomy, nephrotomy, digestive organ resection) that may affect PK profiles of study drugs
- Hypersensitivity to the study drug or any of its excipients
- Known to be human immunodeficiency virus (HIV) positive or positive on viral screen for HIV or viral hepatitis B or hepatitis C
- History of drug or alcohol dependency or abuse within approximately the last 2 years or who have a positive urine drug test or breath alcohol test at Screening or Baseline
- Do not meet the restrictions on concomitant medications, food and beverages (see below)
- Use of illegal (or legalized) recreational drugs in the past year
- Engagement in strenuous exercise within 2 weeks prior to dosing (e.g., marathon runners, weight lifters)
- Currently enrolled in another clinical trial or used any investigational drug or device within 30 days preceding informed consent
- Restrictions on prior and concomitant medications, food and beverages
- Prescription drugs are prohibited within 4 weeks of dosing and over-the-counter drugs within 2 weeks prior to dosing or throughout the Treatment Period
- Smoking or use of tobacco or nicotine-containing products is prohibited within 4 weeks prior to dosing and throughout the Treatment Period
- Intake of caffeinated beverages or food is prohibited within 72 hours prior to dosing and until 72 hours postdose
- Intake of nutritional supplements, juice, and herbal preparations or other foods or beverages that may affect CYP3A4 enzyme or transporters (e.g., alcohol, grapefruit, grapefruit juice, grapefruit-containing beverages, apple or orange juice, vegetables from the mustard green family [e.g., kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard] and charbroiled meats) is prohibited within 2 weeks prior to dosing and throughout the Treatment Period
- Intake of herbal preparations containing St. John's Wort is prohibited within 4 weeks prior to dosing and throughout the Treatment Period
- Any subject that has a known history of malaria or has traveled to a country with known malarial risk (ie, designated as a 'high' or 'moderate' risk country according to the list available athttp://www.cdc.gov/malaria) within the last year
Trial locations and contacts
1 site in 1 country.
About this study
The purpose of this study is to determine the metabolism and excretion of [14C]E2006 in healthy male subjects.
Read the detailed description
This is an open-label, single-dose study in healthy male subjects. The study will have 2 phases: Pretreatment and Treatment. The Pretreatment Phase will last up to 21 days and will consist of a Screening Period and a Baseline Period, during which each subject's eligibility will be determined and assessments will be conducted.
- Conditions
- Metabolism and Excretion
- Being tested
- E2006
- Keywords
- Metabolism and Excretion
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
E2006Drug
Single oral 10mg dose of 100 uCi [14C]E2006
| Study group | Role | What they receive |
|---|---|---|
| E2006 | Experimental | Single oral 10mg dose of 100 uCi [14C]E2006 Receives: Drug: E2006 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pharmacokinetics: Excretion of E2006: urine/feces concentration
Total radioactivity derived from [14C]E2006-related material and E2006 will be analyzed in urine and feces. [14C]E2006 radiolabeled material will be quantified in urine and feces for total radioactivity using a scintillation counting method and/or an accelerator mass spectrometry.
Measured: Up to 35 days
Pharmacokinetics: Plasma concentration of E2006/metabolite
Total radioactivity derived from [14C]E2006-related material, E2006, and metabolites will be analyzed in whole blood, plasma, and red blood cells. [14C]E2006 radiolabeled material will be quantified in whole blood, plasma, red blood cells for total radioactivity using a scintillation counting method and/or accelerator mass spectrometry.
Measured: Up to 816 hours postdose
Secondary outcomes (1)
Pharmacokinetics: Metabolic profile of E2006: plasma/urine/feces concentration
Metabolite profiling in plasma, urine, and feces will be performed by radio-high performance liquid chromatography (radio-HPLC) methods. Metabolites will be identified on the radiochromatograms, and the amount of the each metabolite will be quantified based on the peak areas on the chromatograms. For metabolites detected on the radiochromatograms, LC/MS/MS analysis will be performed to estimate and identify their chemical structures.
Measured: Urine/Feces: Up to 35 days; Plasma: Up to 816 hours postdose
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2014 (estimated)
- Study startFeb 2014
- Primary completionApr 2014
- Study completionMay 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Metabolism and ExcretionStudies of the same condition, open and under way.
- More trials run by Eisai Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 16 participants (actual)
Sponsor and investigators
- Lead sponsor
- Eisai Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02046213
- Sponsor's protocol ID
- E2006-A001-007
- Status last verified
- Nov 2015
- First submitted
- 23 Jan 2014
- Last updated
- 3 Nov 2015
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Nov 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-label, Single-dose Study to Determine the Metabolism and Excretion of [14C]E2006 in Healthy Male Subjects
- ClinicalTrials.gov ID
- NCT02046213
- Acronym / sponsor ID
- E2006-A001-007
- Conditions
- Metabolism and Excretion
- Keywords
- Metabolism and Excretion
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 16 participants (actual)
- Lead sponsor
- Eisai Inc.Industry (pharma, biotech, devices)
- Study start
- Feb 2014
- Primary completion
- Apr 2014 (actual)
- Study completion
- May 2014 (actual)
- First posted
- 27 Jan 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine the metabolism and excretion of [14C]E2006 in healthy male subjects.
Detailed description
This is an open-label, single-dose study in healthy male subjects. The study will have 2 phases: Pretreatment and Treatment. The Pretreatment Phase will last up to 21 days and will consist of a Screening Period and a Baseline Period, during which each subject's eligibility will be determined and assessments will be conducted.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| E2006 | Experimental | Drug: E2006Single oral 10mg dose of 100 uCi [14C]E2006 |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Healthy male 18 to 55 years, inclusive, at the time of informed consent
- Body mass index (BMI) of 18 to 32 kg/m2 at Screening
- Must have had a successful vasectomy (confirmed azoospermia) or they and their female partners must not be of childbearing potential or must be practicing highly effective contraception throughout the study period and for 90 days after study drug discontinuation. No sperm donation is allowed during the study period and for 90 days after study drug discontinuation.
- Provide written informed consent
- Willing and able to comply with all aspects of the protocol
Key exclusion criteria (28 listed)
- Participated in a 14C research study within the 6 months prior to Day -2. The total radiation exposure to radiolabelled compounds from this study and any previous studies must be within the recommended levels considered safe (per US 21 CFR 361.1)
- Exposure to clinically significant radiation (greater than 100 milliseiverts) within 12 months prior to Day -2
- Any history of cerebrovascular disease (stroke or transient ischemic attack)
- A prolonged QT/QTc interval (QTc greater than 450 msec) as demonstrated upon confirmatory ECG if first ECG indicates prolonged QT/QTc interval
- History of prolonged QT/QTc interval
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| E2006Single oral 10mg dose of 100 uCi [14C]E2006 | Drug | E2006 |
Primary outcome
Pharmacokinetics: Excretion of E2006: urine/feces concentration
Time frame: Up to 35 days
Total radioactivity derived from [14C]E2006-related material and E2006 will be analyzed in urine and feces. [14C]E2006 radiolabeled material will be quantified in urine and feces for total radioactivity using a scintillation counting method and/or an accelerator mass spectrometry.
Pharmacokinetics: Plasma concentration of E2006/metabolite
Time frame: Up to 816 hours postdose
Total radioactivity derived from [14C]E2006-related material, E2006, and metabolites will be analyzed in whole blood, plasma, and red blood cells. [14C]E2006 radiolabeled material will be quantified in whole blood, plasma, red blood cells for total radioactivity using a scintillation counting method and/or accelerator mass spectrometry.
1 secondary outcome
Pharmacokinetics: Metabolic profile of E2006: plasma/urine/feces concentration
Time frame: Urine/Feces: Up to 35 days; Plasma: Up to 816 hours postdose
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Nov 2015.
Related trials for Metabolism and Excretion
RecruitingPhase 1
Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
RecruitingPhase 1
Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia
Osteopenia
RecruitingPhase 1
A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma
Healthy Volunteer Study, Healthy Adults
Not yet recruitingPhase 1
A Study of LY4515100 in Healthy Male Participants
Healthy
RecruitingPhase 1
A Study to Learn How ASP3082 is Processed in Healthy Men
Healthy Volunteer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing E2006 in people with Metabolism and Excretion, run by Eisai Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 28 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Nov 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pharmacokinetics: Excretion of E2006: urine/feces concentration (time frame: Up to 35 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Nov 2015.